Talking About Tumors with Ryann and Ryan: Recent Episodes

Talking About Tumors

A medical oncology podcast aimed at residents and fellows to provide an overview of the clinical practice and evidence behind management of each individual tumor site. Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy

View Details

  1. Historical Approach (cytoreduction, IFN-a, sunitinib
  2. Prognostic risk scores
  3. Evidence for modern doublet regimens
  4. Later line therapy

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. Flanigan RC et al. J Urol. 2004;171(3):1071-6. doi:10.1097/01.ju0000110610.61545.ae
  2. Bex A et al. JAMA Oncology. 2019;5(2):164-170. doi:10.1001/jamaoncol.2018.5545
  3. Mejean A et al. NEJM. 2018;379:417-427. doi:10.1056/NEJMoa1803675
  4. Motzer RJ et al. NEJM. 2007;356:115-124. doi:10.1056/NEJMoa065044
  5. Rini BI et al. NEJM. 2019;380:1116-1127. doi:10.1056/NEJMoa1816714
  6. Rini BI et al. JCO. 2023;41(17 Supp). doi:10.1200/JCO.2023.41.17_suppl.LBA4501
  7. Kartolo et al. Urology. 2021;157:8-14. doi:10.1016/j.urology.2021.08.023
  8. Motzer RJ et al. NEJM. 2018;378:1277-1290. doi:10.1056/NEJMoa1712126
  9. Motzer R et al. NEJM. 2021;384:1289-1300. doi:10.1056/NEJMoa2035716
  10. Albiges L et al. Ann Oncol. 2023;34(2 Supp):S1329-S1330. doi:10.1016/j.annonc.2023.10.090
  11. Jonasch E. ASCO Annual Meeting presented May 31, 2024 in Chicago, IL

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. Risk Factors and Presentation
  2. Staging and Paraneoplastic syndromes
  3. Localized Therapy Options and Considerations
  4. Evidence and Limitations for Adjuvant Systemic Therapy

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. Tannock IF et al. Evaluating Trials of Adjuvant Therapy: Is There Benefit for People with Resected Renal Cancer? Journal of Clinical Oncology. 2023;41(15):2713-2717. doi:10.1200/JCO.23.00280/ASSET/IMAGES/LARGE/JCO.23.00280F2.JPEG

  2. Ravaud A et al. NEJM. 2016;375(23):2246-2254. doi:10.1056/NEJMOA1611406/

  3. Pal SK et al. Lancet. 2022;400(10358):1103-1116. doi:10.1016/S0140-6736(22)01658-0

  4. Motzer RJ et al. Lancet. 2023;401(10379):821-832. doi:10.1016/S0140-6736(22)02574-0

  5. Correa AF et al. Eur Urol. 2021;80(1):20-31. doi:10.1016/J.EURURO.2021.02.025

  6. Choueiri TK et al. NEJM. 2024;390(15):1359-1371. doi:10.1056/NEJMOA2312695/

  7. Choueiri TK et al. NEJM. 2021;385(8):683-694. doi:10.1056/NEJMOA2106391/

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. Immunohistochemistry of urothelial cancer
  2. History of systemic therapy in advanced and metastatic disease
  3. Pembrolizumab and Enfortumab Vedotin
  4. Approach to second line therapy and beyond

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. Powles T et al. NEJM. 2024;390(10):875-888. doi:10.1056/NEJMOA2312117/

  2. Powles T et al. NEJM. 2020;383(13):1218-1230. doi:10.1056/NEJMOA2002788/

  3. Galsky MD et al. Lancet. 2020;395(10236):1547-1557. doi:10.1016/S0140-6736(20)30230-0

  4. Powles T et al. Lancet Oncol. 2021;22(7):931-945. doi:10.1016/S1470-2045(21)00152-2

  5. van der Heijden MS et al. NEJM. 2023;389(19):1778-1789. doi:10.1056/NEJMOA2309863/

  6. Von der Maase H et al. JCO. 2000;18(17):3068-3077. doi:10.1200/JCO.2000.18.17.3068/

  7. von der Maase H et al. JCO. 2023;41(23):3881-3890. doi:10.1200/JCO.22.02763

  8. Vuky J et al. . JCO. 2020;38(23):2658-2666. doi:10.1200/JCO.19.01213

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. Etymology, presentation, and work-up of bladder/urothelial cancer
  2. Role of perioperative systemic therapy
  3. Tri-modality therapy (bladder sparing approach)
  4. Considerations for upper tract urothelial cancer

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. Bellmunt J et al. Lancet Oncol. 2021;22(4):525-537. doi:10.1016/S1470-2045(21)00004-8

  2. Birtle AJ et al. JCO. Published online February 13, 2024. doi:10.1200/JCO.23.01659

  3. Birtle A et al. Lancet. 2020;395(10232):1268-1277. doi:10.1016/S0140-6736(20)30415-3

  4. Bajorin DF et al. NEJM. 2021;384(22):2102-2114. doi:10.1056/NEJMOA2034442/

  5. James ND et al. NEJM. 2012;366(16):1477-1488. doi:10.1056/NEJMOA1106106/

  6. Pfister C et al. JCO 2023;41(17_suppl) doi:10.1200/JCO.2023.41.17_SUPPL.LBA4507

  7. Pfister C et al. Eur Urol. 2021;79(2):214-221. doi:10.1016/J.EURURO.2020.08.024

  8. Grossman HB et al. NEJM. 2003;349(9):859-866. doi:10.1056/NEJMOA022148/

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. Clinical presentation and work-up
  2. Intestinal and pancreatobiliary subtypes
  3. Role of perioperative therapy
  4. Considerations for metastatic disease

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. Neoptolemos JP et al. JAMA. 2010;304(10):1073-1081. doi:10.1001/JAMA.2010.1275

  2. Smeenk HG et al.. Ann Surg. 2007;246(5):734-740. doi:10.1097/SLA.0B013E318156EEF3

  3. Chang DK , et al. J Clin Oncol. 2013;31(10):1348-1356. doi:10.1200/JCO.2012.46.8868

  4. Schueneman A et al. Br J Cancer. 2015;113(1):64-68. doi:10.1038/BJC.2015.172

  5. Chiorean EG et al. Journal of the National Comprehensive Cancer Network. 2023;21(7):753-782. doi:10.6004/JNCCN.2023.0034

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. On continuation of ADT and ARAT switch
  2. Systemic therapy options after progression
  3. Improper mandated crossover
  4. PARP inhibitors in prostate cancer

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. Freedland SJ et al. NEJM. 2023;389(16):1453-1465. doi:10.1056/NEJMOA2303974/

  2. de Bono J et al. NEJM. 2020;382(22):2091-2102. doi:10.1056/NEJMOA1911440/

  3. Haslam A, Prasad V. Annals of Oncology. 2018;29(5):1079. doi:10.1093/ANNONC/MDY116

  4. Parker C et al. NEJM. 2013;369(3):213-223. doi:10.1056/NEJMOA1213755/

  5. Khalaf DJ et al. Lancet Oncol. 2019;20(12):1730-1739. doi:10.1016/S1470-2045(19)30688-6

  6. Saad F et al.. J Natl Cancer Inst. 2004;96(11):879-882. doi:10.1093/JNCI/DJH141

  7. Sartor O et al. NEJM. 2021;385(12):1091-1103. doi:10.1056/NEJMOA2107322/

  8. de Wit R et al. NEJM. 2019;381(26):2506-2518. doi:10.1056/NEJMOA1911206/

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. The chemotherapy revolution in prostate cancer
  2. Role of ARATs in earlier disease states
  3. Triple therapy (chemotherapy, ADT, and ARAT)
  4. Considerations for frailer patients with indolent disease

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. Hussain M et al.. J Clin Oncol. 2023;41(20):3595-3607. doi:10.1200/JCO.23.00041

  2. Smith MR et al. NEJM. 2022;386(12):1132-1142. doi:10.1056/NEJMOA2119115/

  3. Fizazi K et al. Lancet. 2022;399(10336):1695-1707. doi:10.1016/S0140-6736(22)00367-1

  4. Sweeney CJ et al. Lancet Oncol. 2023;24(4):323-334. doi:10.1016/S1470-2045(23)00063-3

  5. Wenzel M, et al. Prostate Cancer and Prostatic Diseases 2021 25:2. 2021;25(2):139-148. doi:10.1038/s41391-021-00395-4

  6. Gravis G et al. Lancet Oncol. 2013;14(2):149-158. doi:10.1016/S1470-2045(12)70560-0

  7. James ND et al. NEJM. 2017;377(4):338-351. doi:10.1056/NEJMOA1702900/SUPPL_FILE/

  8. Fizazi K, et al. Lancet Oncol. 2019;20(5):686-700. doi:10.1016/S1470-2045(19)30082-8

  9. James ND et al. Lancet. 2016;387(10024):1163-1177. doi:10.1016/S0140-6736(15)01037-5

  10. Gravis G et al. Lancet Oncol. 2013;14(2):149-158. doi:10.1016/S1470-2045(12)70560-0

  11. Sweeney CJ et al. NEJM. 2015;373(8):737-746. doi:10.1056/NEJMOA1503747/SUPPL_FILE\

  12. James ND et al. The Lancet. 2016;387(10024):1163-1177. doi:10.1016/S0140-6736(15)01037-5

  13. Fizazi K et al. NEJM. 2017;377(4):352-360. doi:10.1056/NEJMOA1704174

  14. Tannock et al. NEJM 2004;351(15):1502-1512. doi:10.1056/NEJMOA040720

  15. Petrylak DP et al.. NEJM. 2004;351(15):1513-1520. doi:10.1056/NEJMOA041318

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. Physiology, efficacy and toxicities of androgen deprivation
  2. Evidence for adjuvant intervention after definitive surgery or radiation
  3. Role of abiraterone in high-risk localized prostate cancer
  4. Limited evidence to support definitive salvage approach

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. Attard G et al. Lancet. 2022;399(10323):447-460. doi:10.1016/S0140-6736(21)02437-5

  2. Xie W et al. J Clin Oncol. 2017;35(27):3097-3104. doi:10.1200/JCO.2017.73.9987

  3. Bolla M et al.. NEJM. 2009;360(24):2516-2527. doi:10.1056/NEJMOA0810095/

  4. Kishan AU et al. Lancet Oncol. 2022;23(2):304-316. doi:10.1016/S1470-2045(21)00705-1

  5. Bolla M et al. Lancet. 2002;360(9327):103-108. doi:10.1016/S0140-6736(02)09408-4

  6. Bolla M et al. Lancet Oncol. 2010;11(11):1066-1073. doi:10.1016/S1470-2045(10)70223-0

  7. Bolla M et al. NEJM. 2009;360(24):2516-2527. doi:10.1056/NEJMOA0810095/

  8. Hanks GE et al. J Clin Oncol. 2003;21(21):3972-3978. doi:10.1200/JCO.2003.11.023

  9. Bolla M et al. Lancet. 2002;360(9327):103-108. doi:10.1016/S0140-6736(02)09408-4

  10. Huggins C, Hodges C V. CA Cancer J Clin. 1972;22(4):293-297. doi:10.3322/CANJCLIN.22.4.232

  11. Huggins C et al. Arch Surg. 1941;43(2):209-223. doi:10.1001/archsurg.1941.01210140043004

  12. Rosenthal SA et al. J Clin Oncol. 2019;37(14):1159-1168. doi:10.1200/JCO.18.02158

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. Background and presentation of prostate Cancer
  2. Evidence behind PSA screening and hallmarks of a screening test
  3. Staging and risk stratification of Localized Disease
  4. Management options and the ProtecT Trial

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1.Schroder F et al. NEJM. 2009; 360(13):1320-1328. doi: 10.1056/NEJMOA0810084/

  1. Andriole G el al. NEJM. 2009; 360(13):1310-1319. doi: 10.1056/NEJMOA0810696/

  2. Lane J et al. Lancet. 2014; 15(10):1109-1118. doi: 10.1016/S1470-2045(14)70361-4

  3. Hamdy F et al. NEJM. 2016; 375(15):1415-1424. doi: 10.1056/NEJMOA1606220

  4. Hamdy F et al. NEJM. 2023; 388(17):1547-1558. doi: 10.1056/NEJMOA2214122/

  5. Ilic D et al. BMJ. 2018; 362:k3519. doi:10.1136/BMJ.K3519

7.Maurer T et al. Nat Rev Urol. 2016;13(4):226-235. doi: 10.1038/nrurol.2016.26. Epub 2016 Feb 23

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

We have updated our initial introduction and are re-posting it here as well as in the initial file.

View Details

  1. Role for definitive chemotherapy and radiation
  2. Controversy on induction chemotherapy
  3. Considerations for nasopharyngeal cancer
  4. Approach to metastatic HNSCC

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. Burtness B et al. J Clin Oncol. 2022;40(21):2321-2332. doi:10.1200/JCO.21.02198

  2. Burtness B et al. Lancet. 2019;394(10212):1915-1928. doi:10.1016/S0140-6736(19)32591-7

  3. Vermorken JB et al. NEJM 2008;359(11):1116-1127. doi:10.1056/NEJMOA0802656

  4. Gibson MK et al. JCO. 2005;23(15):3562-3567. doi:10.1200/JCO.2005.01.057

  5. Zhang L et al. Lancet. 2016;388(10054):1883-1892. doi:10.1016/S0140-6736(16)31388-5

  6. Zhang Y et al. NEJM. 2019;381(12):1124-1135. doi:10.1056/NEJMOA1905287

  7. Gau M et al. Oral Oncol. 2019;95:164-169. doi:10.1016/J.ORALONCOLOGY.2019.06.015

  8. GT W, et al. NEJM. 1991;324(24):1685-1690. doi:10.1056/NEJM199106133242402

  9. Lacas B et al. Radiother Oncol. 2021;156:281. doi:10.1016/J.RADONC.2021.01.013

  10. Bourhis et al. JCO. 2004;22(14_suppl):5505-5505. doi:10.1200/JCO.2004.22.90140.5505

  11. Gyawali B et al. Cancer Treat Rev. 2016;44:10-16. doi:10.1016/J.CTRV.2016.01.002

  12. Forastiere AA et al. J Clin Oncol. 1992;10(8):1245-1251. doi:10.1200/JCO.1992.10.8.1245

  13. Posner MR et al. NEJM. 2007;357(17):1705-1715. doi:10.1056/NEJMOA070956/

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. Anatomy, diagnostic work-up and staging
  2. Field cancerization
  3. Indications for adjuvant concurrent chemoradiation
  4. Evidence to support weekly cisplatin with concurrent radiation

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. Bernier J et al. Head Neck. 2005;27(10):843-850. doi:10.1002/HED.20279

  2. Zevallos JP et al. Head Neck. 2021;43(1):108. doi:10.1002/HED.26465

  3. Young A, Okuyemi OT. StatPearls. Published online January 12, 2023. Accessed October 30, 2023. https://www.ncbi.nlm.nih.gov/books/NBK563022/

  4. Kiyota N et al. J Clin Oncol. 2022;40(18):1980-1990. doi:10.1200/JCO.21.01293

  5. Sharma P et al. J Clin Oncol. 2022;40(16). doi: 10.1200/JCO.2022.40.16_suppl.6004

  6. Cooper JS et al. NEJM. 2004;350(19):1937-1944. doi:10.1056/NEJMOA032646

  7. Bernier J et al. NEJM. 2004;350(19):1945-1952. doi:10.1056/NEJMOA032641

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. Presentation, and considerations for regional mesothelioma
  2. Systemic therapy options for advanced mesothelioma
  3. Corticosteroids for pemetrexed, paclitaxel and docetaxel
  4. A quick review on considerations for LCNEC

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. Peters S et al. Ann Oncol. 2022;33(5):488-499. doi:10.1016/j.annonc.2022.01.074

  2. Baas P et al. Lancet. 2021;397(10272):375-386. doi:10.1016/S0140-6736(20)32714-8

  3. Vogelzang NJ et al. J Clin Oncol. 2003;21(14):2636-2644. doi:10.1200/JCO.2003.11.136

  4. Zalcman G, et al. Lancet. 2016;387(10026):1405-1414. doi:10.1016/S0140-6736(15)01238-6

  5. Santoro A, et al. J Thorac Oncol. 2008;3(7):756-763. doi:10.1097/JTO.0B013E31817C73D6

  6. Lindsay CR et al. Br J Cancer 2021;125(9):1210-1216. doi:10.1038/s41416-021-01407-9

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. Background on SCLC
  2. Approach to treatment by stage
  3. Emerging discussion on prophylactic cranial irradiation
  4. Brief review of basket and umbrella trials

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. Trigo J et al. Lancet Oncol. 2020;21(5):645-654. doi:10.1016/S1470-2045(20)30068-1

  2. O’Brien MER et al. J Clin Oncol. 2006;24(34):5441-5447. doi:10.1200/JCO.2006.06.5821

  3. Rudin CM et al. J Clin Oncol. 2020;38(21):2369-2379. doi:10.1200/JCO.20.00793

  4. Paz-Ares L et al. The Lancet. 2019;394(10212):1929-1939. doi:10.1016/S0140-6736(19)32222-6

  5. Horn L et al NEJM. 2018;379(23):2220-2229. doi:10.1056/NEJMOA1809064/

  6. Lowenbraun S et al. Cancer. 1979;44:406-413. doi:10.1002/1097-0142

  7. Hochstenbag M et al.. J Neurooncol. 2000;48(3):243-248. doi:10.1023/A:1006427407281

  8. Meert AP et al. BMC Cancer. 2001;1(1):1-9. doi:10.1186/1471-2407-1-5/TABLES/4

  9. Fried DB et al. J Clin Oncol. 2004;22(23):4785-4793. doi:10.1200/JCO.2004.01.178

  10. Pignon JP et al. 2010;327(23):1618-1624. doi:10.1056/NEJM199212033272302

  11. Warde P, Payne D. J Clin Oncol. 1992;10(6):890-895. doi:10.1200/JCO.1992.10.6.890

  12. Wong AT et al. J Thorac Oncol. 2016;11(2):242-248. doi:10.1016/J.JTHO.2015.10.011

  13. Lu C et al. Ther Innov Regul Sci. 2021;55(6):1145. doi:10.1007/S43441-021-00315-7

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. Refresher on T+N staging for Stage III
  2. Evidence for concurrent chemoradiation
  3. PACIFIC Trial
  4. Encourage cessation regardless of stage of Lung Cancer

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. Ajani JA et al.. Ann Oncol. 2013;24(11):2844-2849. doi:10.1093/ANNONC/MDT339

  2. Curran WJ et al. J Natl Cancer Inst. 2011;103(19):1452-1460. doi:10.1093/JNCI/DJR325

  3. Vokes EE, et al. JCO. 2007;25(13):1698-1704. doi:10.1200/JCO.2006.07.3569

  4. Dillman RO et al. NEJM. 1990;323(14):940-945. doi:10.1056/NEJM199010043231403

  5. Daly ME et al. JCO. 2022;40(12):1356-1384. doi:10.1200/JCO.21.02528

  6. Spigel DR et al. JCO. 2022;40(12):1301-1311. doi:10.1200/JCO.21.01308

  7. Antonia SJ et al. NEJM. 2017;377(20):1919-1929. doi:10.1056/NEJMOA1709937

  8. Senan et al. JCO. 2016;34(9):953-962. doi:10.1200/JCO.2015.64.8824

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

Background on adjuvant EGFR therapy
Discussion of initial and updated results
Hazard Ratios and Context
When crossover and access limit generalizability

Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.

1.Herbst et al. JCO. 2023;41(10):1830-1840. doi: 10.1200/JCO.22.02186
2.Wu et al. NEJM. 2023;383:1711-1723. doi:10.1056/NEJMoa2027071
3. Tsuboi et al. NEJM. 2023;389(2):137-147. doi: 10.1056/NEJMoa2304594
4. West and Gyawali. JAMA Oncol. 2021;7(5):677-678. doi:10.1001/jamaoncol.2020.6752
5. Gyawali and West. JCO. 2021;39(3):175-177. doi: 10.1200/JCO.20.01762
6. Prasad. Plenary Session. “ADAURA OS Results”. Podcast episode published June 8, 2023
7. Haslan and Prasad. Ann Oncol. 2018; 29(5):1079–1081. doi: 10.1093/annonc/mdy116
8. Tannock et al. JCO. 2023;41(15):2713-2717 doi: 10.1200/JCO.23.00280

Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags
Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. Considerations with surgery, radiation, rate of relapse
  2. Adjuvant chemotherapy
  3. Adjuvant immune checkpoint inhibition
  4. Emerging neoadjuvant trial

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. Spicer J et al. JCO. 2023;41(16_suppl):8521-8521. doi:10.1200/JCO.2023.41.16_SUPPL.8521

  2. Wakelee H et al. NEJM. Published online June 3, 2023. doi:10.1056/NEJMOA2302983

  3. Forde PM et al. NEJM. 2022;386(21):1973-1985. doi:10.1056/NEJMOA2202170

  4. Winton T et al. NEJM. 2005;352(25):2589-2597. doi:10.1056/NEJMOA043623

  5. Stewart et al. BMJ. 1995;311(7010):899-909. doi:10.1136/BMJ.311.7010.899

  6. Arriagada R et al. NEJM. 2004;350(4):351-360. doi:10.1056/NEJMOA031644

  7. Weerakkody Y. Lung cancer (staging - IASLC 8th edition). Radiopaedia.org. Published online January 12, 2017. doi:10.53347/RID-50570

  8. Felip E et al. The Lancet. 2021;398(10308):1344-1357. doi:10.1016/S0140-6736(21)02098-5

  9. Strauss GM et al. J Clin Oncol. 2008;26(31):5043-5051. doi:10.1200/JCO.2008.16.4855

  10. Pignon JP et al. JCO. 2008;26(21):3552-3559. doi:10.1200/JCO.2007.13.9030

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. EGFR inhibitors
  2. ALK inhibitors
  3. Less common molecular targets
  4. Role of KRAS inhibitors and evidence for sotorasib

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. de Langen AJ et al. The Lancet. 2023;401(10378):733-746. doi:10.1016/S0140-6736(23)00221-0

  2. Wolf J et al. NEJM. 2020;383(10):944-957. doi:10.1056/NEJMOA2002787/

  3. Felip E et al. Annals of Oncology. 2021;32(5):620-630. doi:10.1016/j.annonc.2021.02.012

  4. Cho BC et al. J Thorac Oncol. 2017;12(9):1357-1367. doi:10.1016/J.JTHO.2017.07.005

  5. Peters S et al. NEJM. 2017;377(9):829-838. doi:10.1056/NEJMOA1704795/

  6. Solomon BJ et al. JCO. 2018;36(22):2251-2258. doi:10.1200/JCO.2017.77.4794

  7. Solomon BJ et al. NEJM. 2014;371(23):2167-2177. doi:10.1056/NEJMOA1408440

  8. Yang JCH et al. Lancet Oncol. 2015;16(2):141-151. doi:10.1016/S1470-2045(14)71173-8

  9. Soria JC et al. NEJM. 2018;378(2):113-125. doi:10.1056/NEJMOA1713137/

  10. Ramalingam SS et al. NEJM. 2020;382(1):41-50. doi:10.1056/NEJMOA1913662/

  11. Zhang SS et al. Lung Cancer: Targets and Therapy. 2023;14:27. doi:10.2147/LCTT.S403461

  12. Olivier T et al. Transl Oncol. 2023;28:101591. doi:10.1016/J.TRANON.2022.101591

  13. Papadimitrakopoulou VA, et al. Ann Oncol. 2020;31(11):1536-1544. doi:10.1016/J.ANNONC.2020.08.2100

  14. Fukuoka M et al. J Clin Oncol. 2011;29(21):2866-2874. doi:10.1200/JCO.2010.33.4235

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. Evidence to support platinum doublets
  2. The tale of pemetrexed
  3. Immune checkpoint inhibitors alone and in combination
  4. Second Line, approach in progression

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. Paz-Ares L et al. Lancet Oncol. 2021;22(2):198-211. doi:10.1016/S1470-2045(20)30641-0

  2. Hellmann MD et al. NEJM. 2019;381(21):2020-2031. doi:10.1056/NEJMOA1910231

  3. Socinski MA et al. J Thorac Oncol. 2021;16(11):1909-1924. doi:10.1016/J.JTHO.2021.07.009

  4. Reck M et al. NEJM. 2016;375(19):1823-1833. doi:10.1056/NEJMOA1606774

  5. Paz-Ares L et al. NEJM. 2018;379(21):2040-2051. doi:10.1056/NEJMOA1810865

  6. Gandhi L et al. NEJM. 2018;378(22):2078-2092. doi:10.1056/NEJMOA1801005/

  7. Scagliotti G et al. Oncologist. 2009;14(3):253-263. doi:10.1634/THEONCOLOGIST.2008-0232

  8. Paz-Ares L et al. Lancet Oncol. 2012;13(3):247-255. doi:10.1016/S1470-2045(12)70063-3

  9. Paz-Ares LG et al. JCO. 2013;31(23):2895-2902. doi:10.1200/JCO.2012.47.1102

  10. Scagliotti GV et al. JCO. 2008;26(21):3543-3551. doi:10.1200/JCO.2007.15.0375

  11. Delbaldo C et al. JAMA. 2004;292(4):470-484. doi:10.1001/JAMA.292.4.470

  12. Ardizzoni A et al. J Natl Cancer Inst. 2007;99(11):847-857. doi:10.1093/JNCI/DJK196

  13. Temel JS et al. NEJM. 2010;363(8):733-742. doi:10.1056/NEJMOA1000678

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. Presentation and Work-up
  2. Staging and how to memorize staging algorithms
  3. SVC Syndrome, an oncologic emergency
  4. Variations by histology and molecular mutations

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. Patterns of recurrence and approach to stage IV disease
  2. Immunotherapy and BRAF/MEK considerations
  3. Cross trial comparisons
  4. Later line and emerging therapies for advanced melanoma

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

  1. Atkins MB et al. J Clin Oncol. 2023;41(2):186-197. doi:10.1200/JCO.22.01763

  2. Robert C et al. NEJM. 2019;381(7):626-636. doi:10.1056/NEJMOA1904059/

  3. Lebbé C et al. J Clin Oncol. 2019;37(11):867-875. doi:10.1200/JCO.18.01998

  4. Wolchok JD et al. J Clin Oncol. 2022;40(2):127-137. doi:10.1200/JCO.21.02229

  5. Larkin J et al. NEJM. 2015;373(1):23-34. doi:10.1056/NEJMOA1504030

  6. Nathan P et al. NEJM. 2021;385(13):1196-1206. doi:10.1056/NEJMOA2103485

  7. Sarnaik AA et al. J Clin Oncol. 2021;39(24):2656-2666. doi:10.1200/JCO.21.00612

  8. Tawbi HA et al. NEJM. 2022;386(1):24-34. doi:10.1056/NEJMOA2109970

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. Background, staging and work-up of regional melanoma
  2. Evidence for adjuvant and neoadjuvant immunotherapy
  3. Adjuvant BRAF/MEK inhibitor
  4. Considerations for stage IIB/IIC disease

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

  1. Patel SP et al. NEJM. 2023;388(9):813-823. doi:10.1056/NEJMOA2211437/

  2. Weber J et al. NEJM. 2017;377(19):1824-1835. doi:10.1056/NEJMOA1709030

  3. Eggermont AMM et al. NEJM. 2018;378(19):1789-1801. doi:10.1056/NEJMOA1802357

  4. Lao CD. Am Soc Clin Oncol Educ Book. 2022;42(42):1-7. doi:10.1200/EDBK_351153

  5. Faries MB et al. NEJM. 2017;376(23):2211-2222. doi:10.1056/NEJMOA1613210/

  6. Morton DL et al. NEJM. 2014;370(7):599-609. doi:10.1056/NEJMOA1310460/

  7. Welch HG et al. NEJM. 2021;384(1):72-79. doi:10.1056/NEJMSB2019760/

  8. Michielin O et al. Ann Oncol. 2019;30(12):1884-1901. doi:10.1093/ANNONC/MDZ411

  9. Luke JJ et al. Lancet. 2022;399(10336):1718-1729. doi:10.1016/S0140-6736(22)00562-1

  10. Long G V et al. NEJM. 2017;377(19):1813-1823. doi:10.1056/NEJMOA1708539/

  11. Dummer R et al. NEJM. 2020;383(12):1139-1148. doi:10.1056/NEJMOA2005493/

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. History of Immunotherapy
  2. Modern immune checkpoint inhibitors (ICIs)
  3. Unique considerations with ICIs
  4. Immune related adverse events and immortal time bias in observational studies

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

  1. Yadav K, Lewis RJ. JAMA. 2021;325(7):686-687. doi:10.1001/JAMA.2020.9151

  2. Holstead RG et al. Melanoma Res. 2021;31(3):258-263. doi:10.1097/CMR.0000000000000736

  3. Kartolo A et al. J Immunother. 2021;44(4):167-174. doi:10.1097/CJI.0000000000000360

  4. Dolladille C et al. JAMA Oncol. 2020;6(6):865-871. doi:10.1001/JAMAONCOL.2020.0726

  5. Mahmood SS et al. J Am Coll Cardiol. 2018;71(16):1755-1764. doi:10.1016/J.JACC.2018.02.037

  6. Coley WB. Proc R Soc Med. 1910;3(Surg Sect):1. doi:10.1177/003591571000301601

  7. Larkin J et al. NEJM. 2019;381(16):1535-1546. doi:10.1056/NEJMOA1910836/

  8. Wolchok JD et al. Lancet Oncol. 2010;11(2):155-164. doi:10.1016/S1470-2045(09)70334-1

  9. Hodi FS et al. NEJM. 2010;363(8):711-723. doi:10.1056/NEJMOA1003466/SUPPL_FILE/

  10. Brahmer J et al. JCO. 2018;36(17):1714-1768 doi:10.1200/JCO.2017.77.6385

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. BRCA 1/2 genes and relation to malignancy
  2. Family history taking and identifying patients for genetic testing
  3. Risk reduction strategies for breast and ovarian cancer
  4. Systemic therapy considerations in BRCA positive breast cancer

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

  1. Litton JK et al. NEJM. 2018;379(8):753-763. doi:10.1056/NEJMOA1802905/

  2. Geyer CE et al. Ann Oncol. 2022;33(12):1250-1268. doi:10.1016/j.annonc.2022.09.159

  3. Robson M et al. NEJM. 2017;377(6):523-533. doi:10.1056/NEJMOA1706450/

  4. Tutt ANJ et al. NEJM. 2021;384(25):2394-2405. doi:10.1056/NEJMOA2105215/

  5. Risk Reduction and Screening of Cancer in Hereditary Breast-Ovarian Cancer Syndromes | ESMO. Accessed March 13, 2023. https://www.esmo.org/guidelines/guidelines-by-topic/hereditary-syndromes/risk-reduction-screening-hereditary-breast-ovarian-cancer-syndromes

  6. Breast Cancer Screening for Women at High Risk – Cancer Care Ontario. Accessed March 13, 2023. https://www.cancercareontario.ca/en/guidelines-advice/cancer-continuum/screening/breast-cancer-high-risk-women

  7. Chiarelli AM et al. JCO. 2014;32(21):2224-2230. doi:10.1200/JCO.2013.52.8331

  8. Detection, Prevention, and Risk Reduction. Accessed March 13, 2023. https://www.nccn.org/guidelines/category_2

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. Clinical considerations
  2. Neoadjuvant and adjuvant regimens
  3. Immunotherapy in localized and metastatic disease
  4. Later line options in metastatic setting

*Erratum- HER-2 Breast cancer <2cm would benefit from an adjuvant regimen (such as trastuzumab and weekly paclitaxel) but typically neoadjuvant is given to 2cm or greater tumors or those that are node positive.

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

  1. Masuda N et al. NEJM. 2017;376(22):2147-2159. doi:10.1056/NEJMOA1612645/

  2. Zaheed M et al. Cochrane. 2019;2019(2). doi:10.1002/14651858.CD012873.PUB2/

  3. Cortes J et al. The Lancet. 2020;396(10265):1817-1828. doi:10.1016/S0140-6736(20)32531-9

  4. Cortes J et al. NEJM. 2022;387(3):217-226. doi:10.1056/NEJMOA2202809/

  5. Miles D et al. Ann Oncol. 2021;32(8):994-1004. doi:10.1016/j.annonc.2021.05.801

  6. Emens LA et al. Ann Oncol. 2021;32(8):983-993. doi:10.1016/j.annonc.2021.05.355

  7. Schmid P et al. NEJM. 2022;386(6):556-567. doi:10.1056/NEJMOA2112651/

  8. Schmid P et al. NEJM. 2020;382(9):810-821. doi:10.1056/NEJMOA1910549/

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. Role of adjuvant HER-2 Agents and during of therapy
  2. Chemotherapy backbone considerations
  3. Pathologic complete response
  4. Neoadjuvant systemic therapy and response modified approach

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.von Minckwitz G et al. NEJM. 2019;380(7):617-628. doi:10.1056/NEJMOA1814017/

2.von Minckwitz G et al. NEJM. 2017;377(2):122-131. doi:10.1056/NEJMOA1703643/

3.Slamon D et al.. NEJM. 2011;365(14):1273-1283. doi:10.1056/NEJMOA0910383

4.Piccart M et al. JCO. 2021;39(13):1448-1457. doi:10.1200/JCO.20.01204

5.Martin M et al. Lancet Oncol. 2017;18(12):1688-1700. doi:10.1016/S1470-2045(17)30717-9

6.von Minckwitz G et al. NEJM. 2019;380(7):617-628. doi:10.1056/NEJMOA1814017/

7.Gianni L et al. Lancet Oncol. 2014;15(6):640-647. doi:10.1016/S1470-2045(14)70080-4

8.Symmans WF et al.. J Clin Oncol. 2017;35(10):1049-1060. doi:10.1200/JCO.2015.63.1010

9.Gianni L et al. Lancet Oncol. 2016;17(6):791-800. doi:10.1016/S1470-2045(16)00163-7

10.Gianni L et al. Lancet Oncol. 2012;13(1):25-32. doi:10.1016/S1470-2045(11)70336-9

11.Gilboa S et al. Eur J Cancer. 2021;153:190-202. doi:10.1016/J.EJCA.2021.04.044

12.Tolaney SM et al. NEJM. 2015;372(2):134-141. doi:10.1056/NEJMOA1406281/

13.Cameron D et al. Lancet. 2017;389(10075):1195-1205. doi:10.1016/S0140-6736(16)32616-2

14.Earl HM et al. Lancet. 2019;393(10191):2599-2612. doi:10.1016/S0140-6736(19)30650-6

15.Pivot X et al. Lancet. 2019;393(10191):2591-2598. doi:10.1016/S0140-6736(19)30653-1

16.Perez EA et al. J Clin Oncol. 2014;32(33):3744-3752. doi:10.1200/JCO.2014.55.5730

17.Romond EH et al. NEJM. 2005;353(16):1673-1684. doi:10.1056/NEJMOA052122/

18.Ennis S et al.. NEJM. 2001;344(11):783-792. doi:10.1056/NEJM200103153441101

19.Hudis CA. NEJM. 2007;357(1):39-51. doi:10.1056/NEJMRA043186

20.Slamon DJ et al. Science. 1987;235(4785):182-191. doi:10.1126/SCIENCE.3798106

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. Anti-HER2 agent classes
  2. Cleopatra Trial
  3. Later line options
  4. Leptomeningeal carcinomatosis

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

  1. Dawood S et al. NEJM. 2001;344(11):783-792. doi:10.1056/NEJM200103153441101

  2. Baselga J et al. NEJM. 2012;366(2):109-119. doi:10.1056/NEJMOA1113216/

  3. Swain SM et al. NEJM. 2015;372(8):724-734. doi:10.1056/NEJMOA1413513/

  4. Verma S et al. T. NEJM. 2012;367(19):1783-1791. doi:10.1056/NEJMOA1209124/

  5. Cortés J et al. NEJM. 2022;386(12):1143-1154. doi:10.1056/NEJMOA2115022/

  6. Krop IE et al. Lancet Oncol. 2017;18(6):743-754. doi:10.1016/S1470-2045(17)30313-3

  7. Murthy RK et al. NEJM. 2020;382(7):597-609. doi:10.1056/NEJMOA1914609/

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

HER-2 Low Breast Cancer and Sacutuzumab Govetecan

  1. HER-2 Testing Algorithm
  2. Trastuzumab Deruxtecan in HER-2 Low MBC
  3. 2:1 Randomization, Treatment of Provider Choice
  4. Sacutuzumab Govetacan for later line TNBC and HR positive MBC

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.Wolff A et al. JCO. 2018;36(20):2105-2122. doi:10.1200/JCO.2018.77.8738

2.Modi S et al. NEJM. 2022;387(1):9-20. doi:10.1056/NEJMOA2203690/

3.BardiaI A et al. NEJM. 2021;384:1529-1541. doi:10.1056/NEJMOA2028485

4.Rugo H et al. JCO. Published online Aug 26, 2022 . doi:10.1200/JCO.22.01002

5.Rugo H et al. Ann Oncol. 2022;33(suppl_7):S808-S869. doi:10.1016/annonc/annonc1089

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

Thanks to Feed Spot for recognition as one of the best oncology podcasts!
https://blog.feedspot.com/oncology_podcasts/

View Details

  1. Endocrine Resistance: Definition and Mechanism

  2. Role of AI with and without CDK4/6 inhibitors

  3. Later line management of metastatic disease

  4. Informative Censoring and the BOLERO-2 trial

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

  1. Tannock I et al. Ann Oncol. 2020;31(3):331-333. doi:10.1016/J.ANNONC.2019.11.017

  2. André F et al. NEJM. 2019;380(20):1929-1940. doi:10.1056/NEJMOA1813904/

  3. Tannock IF et al.. Annals of Oncology. 2014;25(10):2096. doi:10.1093/annonc/mdu371

  4. Piccart M et al. Ann Oncol. 2014;25(12):2357-2362. doi:10.1093/ANNONC/MDU456

  5. Baselga J et al. NEJM. 2012;366(6):520-529. doi:10.1056/NEJMOA1109653

  6. Gao JJ et al. Lancet Oncol. 2020;21(2):250-260. doi:10.1016/S1470-2045(19)30804-6

  7. Howie LJ et al. JCO. 2019;37(36):3475-3483. doi:10.1200/JCO.18.02217

  8. Im SA et al. NEJM. 2019;381(4):307-316. doi:10.1056/NEJMOA1903765/

  9. Hortobagyi GN et al. NEJM. 2022;386(10):942-950. doi:10.1056/NEJMOA2114663/

  10. Finn RS et al. NEJM. 2016;375(20):1925-1936. doi:10.1056/NEJMOA1607303/

  11. Turner NC et al. NEJM. 2018;379(20):1926-1936. doi:10.1056/NEJMOA1810527/

  12. Robertson JFR et al. Lancet. 2016;388(10063):2997-3005. doi:10.1016/S0140-6736(16)32389-3

  13. Mauri D et al. J Natl Cancer Inst. 2006;98(18):1285-1291. doi:10.1093/JNCI/DJJ357

  14. Lindström LS et al. JCO. 2012;30(21):2601-2608. doi:10.1200/JCO.2011.37.2482

  15. Mouridsen H et al. JCO. 2001;19(10):2596-2606. doi:10.1200/JCO.2001.19.10.2596

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. Recurrence Risk Scores

  2. TailorRx, RxPonder, MINDACT Trials Overview

  3. Introduction to CDK 4/6 inhibitors

  4. PALLAS and MONARCH-E Discussion

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

  1. Johnston SRD et al. JCO. 2020;38(34):3987-3998. doi:10.1200/JCO.20.02514

  2. Harbeck N et al. Ann Oncol. 2021;32(12):1571-1581. doi:10.1016/J.ANNONC.2021.09.015

  3. Mayer EL et al. Lancet Oncol. 2021;22(2):212-222. doi:10.1016/S1470-2045(20)30642-2

  4. Cardoso F et al. NEJM. 2016;375(8):717-729. doi:10.1056/NEJMOA1602253

  5. Kalinsky K et al. NEJM. 2021;385(25):2336-2347. doi:10.1056/NEJMOA2108873/

  6. Sparano JA et al. NEJM. 2019;380(25):2395-2405. doi:10.1056/NEJMOA1904819/

  7. Paik S et al. JCO. 2006;24(23):3726-3734. doi:10.1200/JCO.2005.04.7985

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. Tamoxifen, its development, mechanism and benefits

  2. Aromatase inhibitors and their benefit in post-menopausal state

  3. Nuances on extended endocrine therapy beyond 5 years

  4. SOFT/TEXT, a broad overview of a complex publication

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references on this topic:

  1. Pagani O et al.. NEJM. 2014;371(2):107-118. doi:10.1056/NEJMOA1404037

  2. Francis PA et al. NEJM. 2018;379(2):122-137. doi:10.1056/NEJMOA1803164/

  3. Gnant M et al. NEJM. 2021;385(5):395-405. doi:10.1056/NEJMOA2104162/

  4. Cuzick J et al. Lancet Oncol. 2010;11(12):1135-1141. doi:10.1016/S1470-2045(10)70257-6

  5. Regan MM et al. Lancet Oncol. 2011;12(12):1101-1108. doi:10.1016/S1470-2045(11)70270-4

  6. Davies C et al.. The Lancet. 2013;381(9869):805-816. doi:10.1016/S0140-6736(12)61963-1

  7. Goss PE et al. NEJM. 2016;375(3):209-219. doi:10.1056/NEJMOA1604700/

  8. Goss PE et al. J Natl Cancer Inst. 2005;97(17):1262-1271. doi:10.1093/JNCI/DJI250

  9. Abe O et al. The Lancet. 2011;378(9793):771-784. doi:10.1016/S0140-6736(11)60993-8

  10. Jordan VC. A Breast Cancer Research. 2003;5(6):294. doi:10.1186/BCR656

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. First, second, and third generation chemotherapy regimens

  2. Considerations for anthracyclines

  3. Considerations for taxanes

  4. Adjuvant bisphosphonates

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

  1. Budd GT et al. J Clin Oncol. 2015;33(1):58-64. doi:10.1200/JCO.2014.56.3296

  2. Citron ML et al. J Clin Oncol. 2003;21(8):1431-1439. doi:10.1200/JCO.2003.09.081

  3. Anampa J, Makower D, Sparano JA. BMC Med. 2015;13(1). doi:10.1186/S12916-015-0439-8

  4. Sparano JA et al. J Clin Oncol. 2015;33(21):2353-2360. doi:10.1200/JCO.2015.60.9271

  5. Coleman R et al. Lancet. 2015;386(10001):1353-1361. doi:10.1016/S0140-6736(15)60908-4

  6. Gray R et al. Lancet. 2019;393(10179):1440-1452. doi:10.1016/S0140-6736(18)33137-4

  7. Abe O et al. Lancet. 2005;365(9472):1687-1717. doi:10.1016/S0140-6736(05)66544-0

  8. Albain K et al. Lancet. 2012;379(9814):432. doi:10.1016/S0140-6736(11)61625-5

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. History of surgery and radiation for breast cancer

  2. Indication and goal of adjuvant systemic therapy (incl cell-kill hypothesis)

  3. Overview of breast cancer subtypes

  4. Strategies and guidelines for surveillance

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations at your region of training.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

  1. Bonadonna G, et al. N Engl J Med. 1976;294(8):405-410. doi:10.1056/NEJM197602192940801

  2. Giuliano AE, et al. JAMA. 2017;318(10):918-926. doi:10.1001/JAMA.2017.11470

  3. Abe O et al. Lancet. 2005;365(9472):1687-1717. doi:10.1016/S0140-6736(05)66544-0

  4. Albain K et al. The Lancet. 2012;379(9814):432-444. doi:10.1016/S0140-6736(11)61625-5

  5. Asselain B et al. Lancet Oncol. 2018;19(1):27-39. doi:10.1016/S1470-2045(17)30777-5

  6. Predict Breast. Accessed September 25, 2022. https://breast.predict.nhs.uk/

  7. Masuda N et al. NEJM. 2017;376(22):2147-2159. doi:10.1056/NEJMOA1612645

  8. Berruti A et al J Clin Oncol. 2014;32(34):3883-3891. doi:10.1200/JCO.2014.55.2836

  9. von Minckwitz G et al. J Clin Oncol. 2012;30(15):1796-1804. doi:10.1200/JCO.2011.38.8595

  10. Henry NL et al. J Clin Oncol. 2019;37(22):1965-1977. doi:10.1200/JCO.19.00948

  11. von Minckwitz G et al. NEJM. 2019;380(7):617-628. doi:10.1056/NEJMOA1814017/

  12. Mukherjee Siddhartha. The emperor of all maladies : a biography of cancer. Published 2010.

  13. Harris LN et al. J Clin Oncol. 2016;34(10):1134-1150. doi:10.1200/JCO.2015.65.2289

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. Overview of disease site

  2. Management of localized disease

  3. Surveillance

  4. Metastatic Disease

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

  1. Rao S, Guren MG, Khan K, et al. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Annals of Oncology. 2021;32(9):1087-1100. doi:10.1016/j.annonc.2021.06.015

  2. Morris VK, Salem ME, Nimeiri H, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(4):446-453. doi:10.1016/S1470-2045(17)30104-3

  3. Rao S, Sclafani F, Eng C, et al. International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct. Journal of Clinical Oncology. 2020;38(22):2510-2518. doi:10.1200/JCO.19.03266

  4. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. https://doi.org/101200/JCO19961492527. 2016;14(9):2527-2539. doi:10.1200/JCO.1996.14.9.2527

  5. James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): A randomised, phase 3, open-label, 2×2 factorial trial. Lancet Oncol. 2013;14(6):516-524. doi:10.1016/S1470-2045(13)70086-X

  6. Northover J, Glynne-Jones R, Sebag-Montefiore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010;102(7):1123. doi:10.1038/SJ.BJC.6605605

  7. Nigro ND, Vaitkevicius VK, Considine B. Combined therapy for cancer of the anal canal: A preliminary report. Dis Colon Rectum. 1974;17(3):354-356. doi:10.1007/BF02586980

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. RAPIDO Trial

  2. PRODIGE-23 Trial

  3. OPRA Trial

  4. Evidence for non-operative potential in MSI-H tumors with immune checkpoint inhibition

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

  1. Garcia-Aguilar J, et al. Organ. Journal of Clinical Oncology. 2022;18. doi:10.1200/JCO.22.00032

  2. Cercek A et al. NEJM. 2022;386(25):2363-2376. doi:10.1056/NEJMOA2201445/

  3. July 10, 2020 - EPOV Christopher Hallemeier - The ASCO Post. Accessed August 30, 2022. https://ascopost.com/issues/july-10-2020/epov-christopher-hallemeier/

  4. Thompson H et al. J Clin Oncol. 2021;39(15_suppl). doi:10.1200/JCO.2021.39.15_SUPPL.3509

  5. Conroy T et al. Lancet Oncol. 2021;22(5):702-715. doi:10.1016/S1470-2045(21)00079-6

  6. Bahadoer RR et al. Lancet Oncol. 2021;22(1):29-42. doi:10.1016/S1470-2045(20)30555-6

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

View Details

  1. Anatomy, definitions, and unique considerations vs colon cancer

  2. Surgical modalities and patterns of failure

  3. Perioperative radiation and chemoradiation

  4. Evidence to support adjuvant systemic therapy

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

  1. Delitto D et al. JNCI Journal of the National Cancer Institute. 2018;110(5):460. doi:10.1093/JNCI/DJX228

  2. Bujko K et al. Br J Surg. 2006;93(10):1215-1223. doi:10.1002/BJS.5506

  3. Hong YS et al. J Clin Oncol 2018;36(15_suppl):3501 doi:10.1200/JCO.2018.36.15

  4. Hong YS et al. Journal of Clinical Oncology. 2019;37(33):3111-3123. doi:10.1200/JCO.19.00016

  5. Gérard JP et al. J Clin Oncol. 2006;24(28):4620-4625. doi:10.1200/JCO.2006.06.7629

  6. Roh MS et al. J Clin Oncol. 2009;27(31):5124-5130. doi:10.1200/JCO.2009.22.0467

  7. Sauer R et al. NEJM 2004;351(17):1731-1740. doi:10.1056/NEJMOA040694

  8. Erlandsson J et al. Lancet Oncol. 2017;18(3):336-346. doi:10.1016/S1470-2045(17)30086-4

  9. Folkesson J et al. J Clin Oncol. 2005;23(24):5644-5650. doi:10.1200/JCO.2005.08.144

  10. Sebag-Montefiore D et al. Lancet. 2009;373(9666):811-820. doi:10.1016/S0140-6736(09)60484-0

  11. Kapiteijn E et al. N Engl J Med. 2001;345(9):638-646. doi:10.1056/NEJMOA010580

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. Overview of intrahepatic, perihilar, distal cholangiocarcinoma

  2. Overview of gall bladder adenocarcinoma

  3. Adjuvant chemoradiation and chemotherapy considerations

  4. Per-protocol, intention to treat analysis, historical controls

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

  1. Bridgewater J, Fletcher P, Palmer DH, et al. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. J Clin Oncol. 2022;40(18):2048-2057. doi:10.1200/JCO.21.02568

  2. Primrose JN, Neoptolemos J, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. The Lancet Oncology. 2019;20(5):663-673. doi:10.1016/S1470-2045(18)30915-X

  3. Ebata T, Hirano S, Konishi M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105(3):192-202. doi:10.1002/BJS.10776

  4. Darwish Murad S, Kim WR, Harnois DM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012;143(1). doi:10.1053/J.GASTRO.2012.04.008

  5. Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(12):1015-1027. doi:10.1200/JCO.18.02178

  6. Edeline J, Bonnetain F, Phelip JM, et al. Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. https://doi.org/101200/JCO2017354_suppl225. 2017;35(4_suppl):225-225. doi:10.1200/JCO.2017.35.4_SUPPL.225

  7. Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v28-v37. doi:10.1093/ANNONC/MDW324

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. Overview of nomenclature, etiology and presentation

  2. Management of symptoms and prognosis

  3. Systemic therapy in the first line

  4. Second line and biomarker driven management

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

  1. Marabelle A et al.. J Clin Oncol. 2020;38(1):1-10. doi:10.1200/JCO.19.02105

  2. Lamarca A et al. The Lancet Oncology. 2021;22(5):690-701. doi:10.1016/S1470-2045

  3. Zia MI, Siu LL, et al. Journal of Clinical Oncology. 2005;23(28):6982-6991. doi:10.1200/JCO.2005.06.679

  4. Phelip JM et al. J Clin Oncol. 2022;40(3):262-271. doi:10.1200/JCO.21.00679

  5. Valle J et al. NEJM. 2010;362(14):1273-1281. doi:10.1056/NEJMOA0908721

  6. Oh DY et al. NEJM Evidence. Published online June 1, 2022. doi:https://doi.org/10.1056/EVIDoa2200015

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

View Details

  1. Differential for pancreatic lesion, staging of adenocarcinoma

  2. Surgical considerations, post-surgical complications

  3. Historical adjuvant evidence

  4. An argument for neoadjuvant systemic therapy

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

  1. Fietkau et al. Rl. J Clin Oncol 2022;40(16_suppl) doi:10.1200/JCO.2022.40.16_SUPPL.4008

  2. Conroy T et al. F NE JMe. 2018;379(25):2395-2406. doi:10.1056/NEJMOA1809775/

  3. Tempero MA et al. J Clin Oncol. 2019;37(15_suppl) doi:10.1200/JCO.2019.37.15_SUPPL.4000

  4. Neoptolemos JP et al. The Lancet. 2017;389(10073):1011-1024. doi:10.1016/S0140-6736(16)32409-6/ATTACHMENT/46BFFE67-D3AE-4DEA-822B-4A2CE28139FD/MMC1.PDF

  5. Liao WC et al. Lancet Oncol. 2013;14(11):1095-1103. doi:10.1016/S1470-2045(13)70388-7

  6. van Laethem JL et al. J Clin Oncol. 2010;28(29):4450-4456. doi:10.1200/JCO.2010.30.3446

  7. Evans DB et al. Annals of Surgery. 2000;232(5):727. doi:10.1097/00000658-199912000-00006

  8. Kaiser M, Ellenberg S. Arch Surg. 1985;120(8):899-903. doi:10.1001/ARCHSURG.1985.01390320023003

  9. van Dam JL et al. Eur J Cancer. 2022;160:140-149. doi:10.1016/J.EJCA.2021.10.023

  10. Versteijne E et al. J Clin Oncol. 2022;40(11):1220-1230. doi:10.1200/JCO.21.02233

  11. Neoptolemos et al. NEJM. 2004;350(12):1200-1210. doi:10.1056/NEJMOA032295

  12. Neoptolemos JP et al. Lancet. 2001;358(9293):1576-1585. doi:10.1016/S0140-6736(01)06651-X

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

View Details

  1. Natural history of disease, presentation, and diagnosis

  2. Principles of management

  3. Landmark clinical trials

  4. Targeted therapy options as of 2022

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

  1. Golan T et al. N Engl J Med. 2019;381(4):317-327. doi:10.1056/NEJMOA1903387/

  2. Von Hoff DD et al. N Engl J Med. 2013;369(18):1691-1703. doi:10.1056/NEJMOA1304369/

  3. Conroy T et al. N Engl J Med. 2011;364(19):1817-1825. doi:10.1056/NEJMOA1011923/

  4. Carmichael J et al. Br J Cancer. 1996;73(1):101. doi:10.1038/BJC.1996.18

  5. Casper ES et al. Investig New Drugs 1994 121. 1994;12(1):29-34. doi:10.1007/BF00873232

  6. Rothenberg ML et al. Ann Oncol. 1996;7(4):347-353. doi:10.1093/OXFORDJOURNALS.ANNONC.A010600

  7. New Onset Diabetes Cohort Sought to Unravel Complexities of Pancreatic Cancer Development | Division of Cancer Prevention. https://prevention.cancer.gov/news-and-events/blog/new-onset-diabetes-cohort. Accessed June 13, 2022.

  8. McGuigan A et al. W J Gastroenterology. 2018;24(43):4846-4861. doi:10.3748/WJG.V24.I43.4846

  9. Kamisawa T et al. Pancreatic cancer. Lancet. 2016;388(10039):73-85. doi:10.1016/S0140-6736(16)00141-0

  10. Siegel RL et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. doi:10.3322/CAAC.21708

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

View Details

  1. Principles of management

  2. Key chemotherapy tegimens

  3. Immunotherapy/HER-2 Directed Approach

  4. Alpha spending, hierarchical statistical design

  5. Later line approach and bottom lines to approach

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

  1. Veer E ter et al. J Natl Cancer Inst. 2016;108(10). doi:10.1093/JNCI/DJW166

  2. Guimbaud R et al. J Clin Oncol. 2014;32(31):3520-3526. doi:10.1200/JCO.2013.54.1011

  3. Cunningham D et al. NEJM. 2008;358(1):36-46. DOI: 10.1056/NEJMoa073149

  4. Wagner AD et al. J Clin Oncol. 2006;24(18):2903-2909. doi:10.1200/JCO.2005.05.0245

  5. Janjigian YY et al. Lancet Oncol. 2020;21(6):821-831. doi:10.1016/S1470-2045(20)30169-8

  6. ter Veer et al. Int J Cancer. 2018;143(2):438-448. doi:10.1002/IJC.31325

  7. Doki Y et al. NEJM. 2022;386(5):449-462. doi: 10.1056/NEJMoa2111380.

  8. Shitara K et al. NEJM. 2020;382(25):2419-2430. DOI: 10.1056/NEJMoa2004413

  9. Wilke H et al. The Lancet Oncology. 2014;15(11):1224-1235. doi:10.1016/S1470-2045(14)70420-6

  10. Chao J et al. JAMA Oncol. 2021;7(6):895-902. doi:10.1001/JAMAONCOL.2021.0275

  11. Janjigian YY et al. Lancet. 2021;398(10294):27-40. doi:10.1016/S0140-6736(21)00797-2

  12. Shitara K et al. Nature. 2022;603:7903. doi:10.1038/s41586-022-04508-4

  13. Sun JM et al. The Lancet. 2021;398(10302):759-771. doi:10.1016/S0140-6736(21)01234-4

  14. Shitara K, et al. JAMA Oncology. 2020;6(10):1571-1580. doi:10.1001/JAMAONCOL.2020.3370

  15. Bang YJ et al. Lancet. 2010;376(9742):687-697. doi:10.1016/S0140-6736(10)61121-X

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

View Details

  1. Anatomy of the Upper GI Tract

  2. Diagnosis, Staging Work-up

  3. Neoadjuvant Chemoradiation for Esophageal/EGJ

  4. Perioperative and Adjuvant Gastric/EGJ

  5. Checkmate 577 discussion

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

  1. Ronellenfitsch U et al. Eur J Cancer. 2019;123:101-111. doi:10.1016/J.EJCA.2019.10.001

  2. Ohn J et al. NEJM 2009;345(10):725-730. doi:10.1056/NEJMOA010187

  3. Ell C et al. Gastroenterology. 2000;118(4):670-677. doi:10.1016/S0016-5085(00)70136-3

  4. al-Sarraf M et al. J Clin Oncol. 1997;15(1):277-284. doi:10.1200/JCO.1997.15.1.277

  5. Oba K et al. J Natl Cancer Inst. 2013;105(21):1600-1607. doi:10.1093/JNCI/DJT270

  6. Bang YJ et al. Lancet. 2012;379(9813):315-321. doi:10.1016/S0140-6736(11)61873-4

  7. Smalley SR et al. Journal of Clinical Oncology. 2012;30(19):2327. doi:10.1200/JCO.2011.36.7136

  8. Petrelli F et al. Eur J Cancer. 2017;76:8-16. doi:10.1016/J.EJCA.2017.01.032

  9. Kelly RJ et al. NEJM 2021;384(13):1191-1203. doi:10.1056/NEJMOA2032125/

  10. Al-Batran SE et al. The Lancet. 2019;393(10184):1948-1957. doi:10.1016/S0140-6736(18)32557-1

  11. al-Sarraf M et al.J Clin Oncol. 1997;15(1):277-284. doi:10.1200/JCO.1997.15.1.277

  12. Cunningham D et al. NEJM. 2009;355(1):11-20. doi:10.1056/NEJMOA055531

  13. JS C, et al. JAMA. 1999;281(17):535-547. doi:10.1001/JAMA.281.17.1623

  14. Park SH et al. J Clin Oncol. 2021;32(3):368-374. doi: 10.1016/j.annonc.2020.11.017

  15. Lee J et al. Journal of Clinical Oncology. 2012;30(3):268-273. doi:10.1200/JCO.2011.39.1953

  16. Cats A et al. The Lancet Oncology. 2018;19(5):616-628. doi:10.1016/S1470-2045(18)30132-3

  17. van Hagen P et al. NEJM. 2012;366(22):2074-2084. doi: 10.1056/NEJMoa1112088

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

View Details

IDEA Trial Discussion

  1. Background/Methods

  2. Non-inferiority Trial Design

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

  1. Grothey A et al. NEJM. 2018;378:1177-1188. doi:10.1056/NEJMoa1713709

  2. Andre PT et al. Lancet Oncol. 2020;21(12):1620-1629. doi:https://doi.org/10.1016/S1470-2045(20)30527-1

  3. Mauri LM and D’Agostino RB. NEJM. 2017;377:1357-1367. doi: 10.1056/NEJMra1510063

  4. Hahn S. Korean J Pediatr. 2012;55(11):403-407. doi: 10.3345/kjp.2012.55.11.403

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

View Details

  1. Clinical Presentation, Pathology Evaluation

  2. Chemotherapy Regimens in Adjuvant Setting

  3. Approach to Stage 3

  4. Approach to Stage 2

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

  1. Practice Tools for the prognostic of Colorectal Cancer. Accessed April 2, 2022. https://oncologypro.esmo.org/oncology-in-practice/practice-tools/colorectal-cancer-prognosis

  2. Haller DG et al. Ann Oncol. 2015;26(4):715-724. doi:10.1093/ANNONC/MDV003

  3. Babcock BD et al. Ann Surg Oncol. 2018;25(7):1980-1985. doi:10.1245/S10434-018-6484-8

  4. Moertel CG et al. NEJM. 2010;322(6):352-358. doi:10.1056/NEJM199002083220602

  5. Ribic CM et al. NEJM. 2003;349(3):247-257. doi:10.1056/NEJMOA022289

  6. Haller DG et al. J Clin Oncol. 2005;23(34):8671-8678. doi:10.1200/JCO.2004.00.5686

  7. Kuebler JP et al. J Clin Oncol. 2007;25(16):2198-2204. doi:10.1200/JCO.2006.08.2974

  8. André T et al. J Clin Oncol. 2009;27(19):3109-3116. doi:10.1200/JCO.2008.20.6771

  9. Sargent DJ et al. J Clin Oncol. 2005;23(34):8664-8670. doi:10.1200/JCO.2005.01.6071

  10. Kannarkatt J et al. J Oncol Pract. 2017;13(4):233-241. doi:10.1200/JOP.2016.017210

  11. Grothey A et al. NEJM. 2018;378(13):1177-1188.

  12. André T et al. Lancet Oncol. 2020;21(12):1620-1629. doi:10.1016/S1470-2045(20)30527-1

  13. André T et al. J Clin Oncol. 2009;27(19):3109-3116. doi:10.1200/JCO.2008.20.6771

  14. André T et al. Oxaliplatin, NEJM 2009;350(23):2343-2351. doi:10.1056/NEJMOA032709

  15. Buyse M et al. Stat Methods Med Res. 2008;17(5):467-475. doi:10.1177/0962280207081864

  16. Sargent D et al. Eur J Cancer. 2011;47(7):990. doi:10.1016/J.EJCA.2010.12.015

  17. Gray R et al. Lancet. 2007;370(9604):2020-2029. doi:10.1016/S0140-6736(07)61866-2

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

View Details

  1. Background on molecular targeted agents

  2. VEGF-inhibitors

  3. EGFR inhibition

  4. Left vs Right sided colon cancer

  5. MSI-H/dMMR status

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

  1. Botrel TEA et al. BMC Cancer. 2016;16(1):1-19. doi:10.1186/S12885-016-2734-Y/FIGURES/5

  2. Deng T et al. Medical Oncol 2013 30:4. 2013;30(4):1-5. doi:10.1007/S12032-013-0752-Z

  3. Hurwitz H et al. NEJM. 2009;350(23):2335-2342. doi:10.1056/NEJMOA032691

  4. Booth CM, Goodman AM. Nature Rev Clinl Oncol 2021 18:11. 2021;18(11):673-674. doi:10.1038/s41571-021-00550-9

  5. Booth C. J Clin Oncol. 2008;26(28):4693-4694. doi:10.1200/JCO.2008.18.8060

  6. Saltz LB et al. J Clin Oncol. 2008;26(12):2013-2019. doi:10.1200/JCO.2007.14.9930

  7. Stathopoulos GP et al. Oncology. 2010;78(5-6):376-381. doi:10.1159/000320520

  8. Tang W et al. J Clin Oncol. 2020;38(27):3175-3184. doi:10.1200/JCO.20.00174

  9. Giantonio BJ et al. J Clin Oncol. 2007;25(12):1539-1544. doi:10.1200/JCO.2006.09.6305

  10. van Cutsem E et al. NEJM. 2009;360(14):1408-1417.

  11. Cutsem E van, et al. J Clin Oncol. doi:10.1200/JCO.2010.28.15_SUPPL.3570

  12. Bokemeyer C et al. Eur J Cancer. 2012;48(10):1466-1475. doi:10.1016/J.EJCA.2012.02.057

  13. Tejpar S et al. JAMA Oncol. 2017;3(2):194-201. doi:10.1001/JAMAONCOL.2016.3797

  14. Venook AP et al. JAMA. 2017;317(23):2392-2401. doi:10.1001/JAMA.2017.7105

  15. Maughan TS et al. The Lancet. 2011;377(9783):2103-2114

  16. Lenz HJ et al. J Clin Oncol. 2019;37(22):1876-1885. doi:10.1200/JCO.18.02258

  17. Venook A et al. Ann Oncology. 2014;25(2):ii112. doi:10.1093/ANNONC/MDU193.19

  18. Shiu KK et al. J Clin Oncol https://doi.org/101200/JCO2021393_suppl6. 2021;39(3_suppl):6-6. doi:10.1200/JCO.2021.39.3_SUPPL.6

  19. André T et al. NEJM 2020;383(23):2207-2218.

  20. Jonker DJ al. NEJM. 2009;2(11):2040-2048. doi:10.1056/NEJMOA071834

  21. Brulé SY et al. Eur J Cancer. 2015;51(11):1405-1414. doi:10.1016/J.EJCA.2015.03.015

  22. Tol J et al. NEJM. 2009;360(6):563-572.

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

View Details

  1. Clinical presentations of metastatic colon cancer

  2. ECOG performance status

  3. 5-fluorouracil and capecitabine

  4. Doublet Regimens (FOLFOX/FOLFIRI and derivatives)

  5. FOLFOXIRI

  6. Considerations for elderly/frail patients

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode

  1. Cremolini C, et al. Lancet Oncol. 2020;21(4):497-507. doi:10.1016/S1470-2045(19)30862-9

  2. Cremolini C et al. Lancet Oncol. 2015;16(13):1306-1315. doi:10.1016/S1470-2045(15)00122-9

  3. Sobrero AF et al. J Clin Oncol. 2016;15(1):368-381. doi:10.1200/JCO.1997.15.1.368

  4. Pinedo HM, Peters GFJ. J Clin Oncol. 1988;6(10):1653-1664. doi:10.1200/JCO.1988.6.10.1653

  5. Loriot MA, et al. Bulletin du Cancer. 2018;105(4):397-407. doi:10.1016/J.BULCAN.2018.02.001

  6. Pachman DR et al. J Clin Oncol. 2015;33(30):3416-3422. doi:10.1200/JCO.2014.58.8533

  7. Eonard L et al. NEJM. 2009;343(13):905-914. doi:10.1056/NEJM200009283431302

  8. Falcone A et al. J Clin Oncol. 2007;25(13):1670-1676. doi:10.1200/JCO.2006.09.0928

  9. Tournigand C et al. J Clin Oncol. 2004;22(2):229-237. doi:10.1200/JCO.2004.05.113

  10. Group NGTAT. J Clin Oncol. 2016;10(6):904-911. doi:10.1200/JCO.1992.10.6.904

  11. Jang RW et al. J Oncol Practice. 2014;10(5):e335-e341. doi:10.1200/JOP.2014.001457

  12. Simmonds PC, et al. B J Cancer 2006 94:7. 2006;94(7):982-999. doi:10.1038/sj.bjc.6603033

  13. Douillard JY et al. Lancet. 2000;355(9209):1041-1047. doi:10.1016/S0140-6736(00)02034-1

  14. de Gramont A et al. J Clin Oncol. 2016;15(2):808-815. doi:10.1200/JCO.1997.15.2.808

  15. O’connell MJ. Cancer. 1989;63:1026-1030. doi:10.1002/1097-0142

  16. Poon MA et al. J Clin Oncol. 2016;7(10):1407-1418. doi:10.1200/JCO.1989.7.10.1407

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

View Details

Overview of our podcast and goal.